Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,083 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Surgical Management Clear all

Conditions: Obesity, Bariatric Surgery Candidate, Weight Loss
Interventions: Outcomes; Other
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Colorectal Disorders, Anorectal Disorder, Patient Satisfaction, Pain, Postoperative, Opioid Use, Opioid Abuse, Opioid Dependence
Interventions: ReCOVER Enhanced Recovery Protocol; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Arthroscopic Surgery, Nutrition, Orthopedic Surgery, Shoulder Arthroscopic Surgery, Knee Arthroscopic Surgery
Interventions: Standard of Care, Nutritional Video; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 10 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Soft Tissue Sarcoma, Stage I Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities, Stage III Soft Tissue Sarcoma of the Trunk and Extremities
Interventions: Computed Tomography, Educational Intervention, Magnetic Resonance Imaging, Physical Therapy, Questionnaire Administration, Telemedicine; Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Pelvic Organ Prolapse (POP), Stress Urinary Incontinence (SUI), Postoperative Pain
Interventions: Suzetrigine, Opioid Analgesics (Tramadol or Oxycodone), Scheduled Acetaminophen and Ibuprofen; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: alemtuzumab, cyclosporine, fludarabine phosphate, melphalan, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreatic Neoplasms, Pancreatic Adenocarcinoma
Interventions: Hyperthermic intraperitoneal chemotherapy, Open pancreaticoduodenectomy, Gemcitabine; Procedure · Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: End Stage Renal Disease
Interventions: Graft placement surgery plus Trinam therapy; Procedure
Lead sponsor: Ark Therapeutics Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 12
States / cities: Long Beach, California • Paducah, Kentucky • Baton Rouge, Louisiana + 8 more

Conditions: Glioblastoma Multiforme
Interventions: CAR.B7-H3T cells infusion; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Persistent Post-surgical Pain, Acceptance and Commitment Therapy, Substance Use Disorder
Interventions: ACT (Acceptance and Commitment Therapy); Behavioral
Lead sponsor: Barbara A Rakel; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Mastectomy; Lymphedema
Interventions: Cryoneurolysis, Sham Comparator; Device
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 5
States / cities: Los Angeles, California • San Diego, California • Gainesville, Florida + 2 more

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: filgrastim, carboplatin, cyclophosphamide, etoposide, vincristine sulfate, radiation therapy, Mesna, therapeutic conventional surgery; Biological · Drug · Radiation + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 140
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 118 more

Conditions: Prostate Cancer, Localized Prostate Carcinoma
Interventions: Leuprolide, Degarelix, Relugolix, Triptorelin, Bicalutamide, 18-F Flotufolastat PSMA PET, Radical prostatectomy; Drug · Diagnostic Test · Procedure
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older · Male only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Bladder Carcinoma
Interventions: Gabapentin, Placebo, Questionnaire Administration; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: Decision Aid (DA), Standard of Care (SOC); Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Aurora, Colorado • Denver, Colorado • Highlands Ranch, Colorado

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Panitumumab, Surgery, Radiation Therapy; Drug · Procedure
Lead sponsor: Neal Ready; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: Nivolumab, Surgical Resection, Radiation (5 days), Radiation (3 days); Drug · Procedure · Radiation
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chronic Neuropathic Pain
Interventions: Surgical Management of Neuroma; Procedure
Lead sponsor: Axogen Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Tampa, Florida • Indianapolis, Indiana • Salt Lake City, Utah + 1 more

Conditions: Skull Base Neoplasms, Skull Neoplasms, Bone Neoplasm, Neoplasms, Bone Diseases, Musculoskeletal Disease
Interventions: near-infrared light nasal endoscope used with ICG; Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Barrett Esophagus, GERD
Interventions: Cytosponge, Transnasal Endoscopy (TNE), Esophagogastroduodenoscopy; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Left Sided Heart Failure, Left Ventricular Assist Device, Anticoagulant Therapy, Gastro Intestinal Bleeding, Thrombosis, LVAD, Anti-factor Xa, aPTT, Heparin
Interventions: aPTT guided heparin management, Anti-factor Xa guided heparin management; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Recurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Childhood Neuroblastoma, Refractory Childhood Osteosarcoma, Refractory Neuroblastoma, Refractory Osteosarcoma
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cyclophosphamide, Echocardiography Test, Fludarabine Phosphate, GD2-CAR-expressing Autologous T-lymphocytes, Imaging Procedure, Magnetic Resonance Imaging of the Heart, Multigated Acquisition Scan, Questionnaire Administration; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 40 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2040
U.S. locations: 6
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 3 more

Conditions: Multiple Myeloma, End Stage Renal Disease
Interventions: Cyclophosphamide, anti-thymocyte globulin, Kidney transplant, Thymic irradiation, Bone marrow transplant from a related donor; Drug · Procedure · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetic Macular Edema
Interventions: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Intravitreal Ranibizumab 0.5 mg Injection, Ranibizumab refill exchange; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 89
States / cities: Mesa, Arizona • Phoenix, Arizona • Bakersfield, California + 79 more

Search by objective public record fields.

The Collateral Impact of Bariatric Surgery on Families

A Multimodal Enhanced Recovery Program in Anorectal Surgery

The Effect of Nutritional Education on Post-Arthroscopic Nutritional Status

Individualized Prehabilitation for Enhancing Recovery and Surgical Outcomes in Patients Undergoing Radiotherapy and Surgery for Soft Tissue Sarcoma

Suzetrigine for Opioid-Sparing Postoperative Analgesia Following Transvaginal Pelvic Reconstructive Surgery

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma

Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence

Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

Preventing Persistent Post-Surgical Pain and Opioid Use In At-Risk Veterans: Effect of ACT

Ultrasound-Guided Percutaneous Cryoneurolysis to Treat Postoperative Pain After Mastectomy

Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy

A Novel Patient Decision Aid for Surgical Treatment Options in Early-Stage Breast Cancer

Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer

Surgical Treatment of Chronic Neuropathic Pain

Proposal for Intraoperative Administration of Intravenous Indocyanine Green to Evaluate Position of the Optic Canal, Position of the Internal Carotid Arteries, Tumor Vascularization, and Vessel Encasement in Endoscopic Endonasal Cranial Base Surgery

Patient Acceptance and Preference Among Screening Modalities for Detection of Barrett's Esophagus

Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial

Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial

Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME